"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at bortezomib, doxorubicin and dexamethasone for myeloma that has come back or stopped responding to treatment
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at 3 drugs called bortezomib (Velcade), doxorubicin and dexamethasone for myeloma that has come back or stopped responding to treatment.
Doctors often treat myeloma with chemotherapy, but sometimes the treatment stops working or the myeloma comes back (
Bortezomib is a type of biological therapy called a proteasome inhibitor. It is currently used on its own to treat myeloma that has come back after chemotherapy. In this trial, the researchers are looking at bortezomib in combination with other drugs.
The aim of the trial is to find out if a combination of bortezomib, doxorubicin and dexamethasone helps people who have already had chemotherapy for myeloma.
Who can enter
You can enter this trial if you
- Have myeloma that has come back (relapsed) or stopped responding to treatment
- Have already had a chemotherapy regime that included doxorubicin and dexamethasone
- Are well enough to take part (performance status 0, 1, 2 or 3
- Have satisfactory blood test results
- Have satisfactory test results for heart function
- Are willing to use reliable contraception if there is any chance you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this trial if you
- Have no myeloma proteins showing up in your blood or urine tests (non secretory myeloma)
- Have already had more than 6 cycles of VAD chemotherapy
- Have damage to the nerves in your hands or feet (peripheral neuropathy) from earlier chemotherapy
- Have had more than one autologous stem cell transplant
- Have had any other cancer in the last five years, apart from non melanoma skin cancer or carcinoma in situ of the cervix that has been successfully treated
- Have had a plasma exchange in the last 3 weeks
- Have had any other experimental drug as part of a clinical trial in the last 4 weeks
- Have had bortezomib (Velcade) before
- Have had an allergic reaction to boron or mannitol
- Have any other medical condition that could affect you taking part in the trial
- Are known to be HIV, hepatitis B or hepatitis C positive
- Are pregnant or breastfeeding
This is a phase 2 trial. It will recruit 69 patients in Ireland and the UK. Everybody taking part will have bortezomib, doxorubicin and dexamethasone.
You have 3 week (21 day) cycles of treatment. You have bortezomib as an injection into a vein on days 1, 4, 8 and 11 of each cycle. This will take a few minutes.
Starting on day 1, you have the doxorubicin slowly over 4 days through an infusion pump. For this, you need to have a central line.
Dexamethasone is a tablet that you take for 4 days at a time. You have it on days 1 to 4, 8 to 11 and 15 to 18 of each treatment cycle.
You will have between 4 and 6 cycles of treatment, depending on how much it is helping you.
You will see the doctors and have some tests before you start treatment. The tests include
- Physical examination
- Blood tests
- Urine test
- Bone marrow test
- Heart scan (
- Bone scan
You go to the hospital daily for the first 4 days of each treatment cycle. You see the trial doctors every 2 weeks during your treatment and you have blood tests at each visit. If the doctors think you need to have any other tests or scans, they will discuss this with you.
When you finish treatment, you will have follow up appointments at least every 2 months for a year.
Bortezomib is still quite a new drug and there may be some side effects the doctors don’t know about yet. In trials so far, the most common side effects have been
- Tiredness (fatigue)
- Constipation or diarrhoea
- Feeling or being sick
- Loss of appetite
- Weight loss
- Numbness or tingling in the hands or feet
- A drop in your blood count causing an increased risk of infection, bruising or bleeding problems and tiredness
How to join a clinical trial
Professor T C M Morris
Experimental Cancer Medicine Centre (ECMC)
Cancer Trials Ireland